Savara Inc (NASDAQ:SVRA) Position Boosted by JPMorgan Chase & Co.

JPMorgan Chase & Co. raised its position in shares of Savara Inc (NASDAQ:SVRA - Free Report) by 1,948.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,423,139 shares of the company's stock after acquiring an additional 1,353,649 shares during the period. JPMorgan Chase & Co. owned approximately 0.83% of Savara worth $4,369,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in SVRA. Cibc World Markets Corp purchased a new stake in shares of Savara during the 4th quarter worth about $33,000. KLP Kapitalforvaltning AS purchased a new stake in Savara during the fourth quarter worth approximately $41,000. Virtu Financial LLC acquired a new stake in shares of Savara in the third quarter worth $67,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Savara by 14.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 36,390 shares of the company's stock valued at $112,000 after acquiring an additional 4,732 shares during the period. Finally, SG Americas Securities LLC raised its stake in shares of Savara by 14.0% in the 4th quarter. SG Americas Securities LLC now owns 51,589 shares of the company's stock valued at $158,000 after acquiring an additional 6,330 shares during the period. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Savara Stock Down 0.2 %

SVRA traded down $0.01 on Thursday, reaching $3.24. The company's stock had a trading volume of 50,331 shares, compared to its average volume of 1,308,939. The stock has a market cap of $560.02 million, a price-to-earnings ratio of -7.50 and a beta of 0.52. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. The business's 50 day moving average is $2.76 and its 200 day moving average is $3.08. Savara Inc has a 1 year low of $2.26 and a 1 year high of $5.31.

Savara (NASDAQ:SVRA - Get Free Report) last issued its earnings results on Thursday, March 27th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.02). The firm had revenue of $0.27 million for the quarter. As a group, research analysts forecast that Savara Inc will post -0.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a "buy" rating and issued a $6.00 price target on shares of Savara in a report on Friday, March 28th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $8.83.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.